RPHM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RPHM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Reneo Pharmaceuticals's Short-Term Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.33 Mil.
Reneo Pharmaceuticals's quarterly Short-Term Capital Lease Obligation stayed the same from Dec. 2023 ($0.33 Mil) to Mar. 2024 ($0.33 Mil) and stayed the same from Mar. 2024 ($0.33 Mil) to Jun. 2024 ($0.33 Mil).
Reneo Pharmaceuticals's annual Short-Term Capital Lease Obligation increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.40 Mil) but then declined from Dec. 2022 ($0.40 Mil) to Dec. 2023 ($0.33 Mil).
The historical data trend for Reneo Pharmaceuticals's Short-Term Capital Lease Obligation can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reneo Pharmaceuticals Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Short-Term Capital Lease Obligation | - | - | - | 0.40 | 0.33 |
Reneo Pharmaceuticals Quarterly Data | |||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Short-Term Capital Lease Obligation | Get a 7-Day Free Trial | 0.32 | 0.33 | 0.33 | 0.33 | 0.33 |
Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.
Thank you for viewing the detailed overview of Reneo Pharmaceuticals's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.
Ashley Hall | officer: Chief Development Officer | C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Niall O'donnell | director | C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105 |
Michael Cruse | officer: Senior VP, Corporate Operation | C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130 |
Roshawn A. Blunt | director | 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130 |
Jennifer Lam | officer: VP of Finance & Administration | C/O RENEO PHARMACEUTICALS, INC., 18575 JAMBOREE ROAD, SUITE 275-S, IRVINE CA 92612 |
Paul W. Hoelscher | director | 1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015 |
Vineet R. Jindal | officer: Chief Financial Officer | C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130 |
Gregory J. Flesher | director, officer: President and CEO | 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612 |
Bali Muralidhar | director | C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077 |
Wendy S. Johnson | officer: Chief Development Officer | 800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219 |
New Enterprise Associates 15, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Rivervest Venture Fund Iii (ohio), L.p. | 10 percent owner | 11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502 |
Rivervest Venture Fund Iii, L.p. | 10 percent owner | 7733 FORSYTH BOULEVARD, ST. LOUIS MO 63105 |
Stacey Denenberg Seltzer | director | C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
From GuruFocus
By PRNewswire • 06-24-2024
By sperokesalga sperokesalga • 05-31-2023
By GuruFocus Research • 11-13-2023
By Marketwired • 11-02-2023
By GuruFocus Research • 02-08-2024
By Marketwired • 10-25-2023
By PRNewswire • 05-14-2024
By Marketwired • 10-09-2023
By sperokesalga sperokesalga • 05-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.